Literature DB >> 9652895

Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis.

M Kato1, Y Miwa, M Tajika, T Hiraoka, Y Muto, H Moriwaki.   

Abstract

We analyzed basal energy metabolism in 20 healthy volunteers and 41 cirrhotic patients by indirect calorimetry. Subjects were then given either glucose, branched-chain amino acids (BCAA) or fatty acids as an energy substrate. Resting energy expenditure (REE), nonprotein respiratory quotient (npRQ), and oxidation rates of glucose (% CHO), protein (% PRO) and fat (% FAT) were analyzed. REE and %FAT were significantly higher and % CHO and %PRO were significantly lower in cirrhosis than in controls. These changes correlated with disease severity. Glucose and BCAA were utilized efficiently as energy substrates and reduced %FAT in cirrhosis. Energy efficacy (increased energy expenditure/energy equivalent of the supplemented nutrient) was significantly higher in BCAA (96 +/- 16%) than in glucose (41 +/- 8%) (p<0.01) and fatty acids (27 +/- 13%) (p<0.05). Patients with cirrhosis have an increased energy requirement. BCAA seems to be the preferred substrate to meet this demand, because its energy efficacy is higher than glucose or fatty acids in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652895     DOI: 10.2169/internalmedicine.37.429

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  15 in total

Review 1.  Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses.

Authors:  Pranav Periyalwar; Srinivasan Dasarathy
Journal:  Clin Liver Dis       Date:  2012-01-23       Impact factor: 6.126

Review 2.  Branched-chain amino acids in liver diseases.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 3.  Branched-chain amino acids in liver diseases.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-30

Review 4.  Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.

Authors:  Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 5.  Nutrition and exercise in the management of liver cirrhosis.

Authors:  Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

6.  Sarcopenia in Liver Transplantation.

Authors:  John Montgomery; Michael Englesbe
Journal:  Curr Transplant Rep       Date:  2019-01-21

7.  Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease.

Authors:  Miwa Kawanaka; Ken Nishino; Takahito Oka; Noriyo Urata; Jun Nakamura; Mitsuhiko Suehiro; Hirofumi Kawamoto; Yasutaka Chiba; Gotaro Yamada
Journal:  Hepat Med       Date:  2015-06-03

8.  Two randomized controlled studies comparing the nutritional benefits of branched-chain amino acid (BCAA) granules and a BCAA-enriched nutrient mixture for patients with esophageal varices after endoscopic treatment.

Authors:  Yoshiyuki Sakai; Yoshinori Iwata; Hirayuki Enomoto; Masaki Saito; Kazunori Yoh; Akio Ishii; Tomoyuki Takashima; Nobuhiro Aizawa; Naoto Ikeda; Hironori Tanaka; Hiroko Iijima; Shuhei Nishiguchi
Journal:  J Gastroenterol       Date:  2014-03-17       Impact factor: 7.527

9.  Metabolic responses to Orientia tsutsugamushi infection in a mouse model.

Authors:  Jeeyoun Jung; Youngae Jung; Byoungchul Gill; Changhun Kim; Kyu-Jam Hwang; Young-Ran Ju; Hye-Ja Lee; Hyuk Chu; Geum-Sook Hwang
Journal:  PLoS Negl Trop Dis       Date:  2015-01-08

10.  Nutrition therapy for liver diseases based on the status of nutritional intake.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Manabu Nakashima; Kazuhiro Kotoh; Makoto Nakamuta; Munechika Enjoji
Journal:  Gastroenterol Res Pract       Date:  2012-11-14       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.